Greenphire Launches GreenSpace App
Greenphire has unveiled a new patient-facing digital platform, GreenSpace.
GreenSpace offers a unified digital experience accessible via iOS and Android devices, or through an internet browser. The platform provides access to trial-related information and activities such as financial views and account details, submission of receipts for reimbursement, visit and travel itinerary details, delivery of surveys and insights, and more.
In addition to GreenSpace, Greenphire has also expanded its payment offerings available through ClinCard. The solution will offer a suite of payment modalities for both banked and unbanked study populations. This provides patients with the ability to choose from options that best align with their personal needs, including reloadable debit cards, virtual cards, digital wallets, email to money and bank transfers that are real-time, low cost to customers, and zero fees for patients.
Reference
Greenphire Launches GreenSpace App and Expands Global Payment Functionality. (2023, April 25). Cision PR Newsire.
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
